Skip to search formSkip to main contentSkip to account menu

panobinostat

Known as: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)- 
A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing… 
National Institutes of Health

Related topics

Related topics

11 relations
Angiogenesis InhibitionHistone DeacetylaseNCIt Antineoplastic Agent TerminologyPositive Regulation of Apoptosis

Broader (4)

Antineoplastic AgentsHistone deacetylase inhibitorHydroxamic AcidsIndoles

Narrower (1)

LBH589

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity.
Histone acetyl transferases (HATs) and histone deacetylases (HDACs) are antagonistic enzymes regulating the turnover of histone… 
2015
2015
The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
Review
2014
Review
2014
Rationale for combination therapy in myelofibrosis.
2013
2013
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
Panobinostat is a histone deacetylase inhibitor that has shown synergistic preclinical anti-myeloma activity when combined with… 
2013
2013
Significant improvement of pig cloning efficiency by treatment with LBH589 after somatic cell nuclear transfer.
2012
2012
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
SummaryObjective The objective was to determine the maximum tolerated dose and the dose-limiting toxicity of panobinostat (LBH589… 
Highly Cited
2012
Highly Cited
2012
Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.
Review
2012
Review
2012
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Hodgkin's lymphoma (HL) is diagnosed in 20,000 men and women annually in North America and Europe. Despite treatment advancements… 
2011
2011
The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines
SummaryAlthough platinum based therapy has improved short term survival of patients with metastatic ovarian cancer, the majority… 
Highly Cited
2010
Highly Cited
2010
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression
Aromatase converts androgens to estrogens. Although third-generation aromatase inhibitors (AIs) are important drugs in hormonal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)